Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy and Pharmacogenomic Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HLA-B drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HLA-B ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View HLA-B Products |
| Gene Delivery | HLA-B Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View HLA-B Products |
| Benchmark Ab | Anti-HLA-B (Sequence of Benchmark) Recombinant positive control. |
View HLA-B Products |
| Validator | HLA-B siRNA Set For knockdown verification. |
View HLA-B Products |
| Related Target A | B2M Essential subunit for stable MHC Class I complex formation. |
View B2M Products |
| Related Target B | HLA-A Major paralog for cross-reactivity and specificity screening. |
View HLA-A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| pMHC Complex Stability | Recombinant proteins optimized for stable peptide loading, High Purity (>95%) |
| Allele Cross-Reactivity | Sequence-verified paralogs (HLA-A, HLA-C) available for strict counter-screening |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live HLA-B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HLA-B targeted therapeutics and diagnostics is intensifying, with major players shifting focus toward precision immunotherapies like TCR-T cells and TCR-mimic (TCRm) antibodies. As first-generation therapies targeting common HLA alleles reach the clinic, the next wave of R&D is targeting diverse HLA-B allotypes to expand patient coverage in solid tumors and managing severe pharmacogenomic liabilities (e.g., HLA-B*15:02, HLA-B*57:01).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| TCR-T Cell Therapy | Immatics, Immunocore | Solid Tumors | Tetramer Staining (Need high-purity pMHC complexes) |
| TCRm Antibody | T-knife, Eureka | Oncology | Affinity/Specificity (Need diverse HLA allele panel) |
| Diagnostic/CDx | Various | Pharmacogenomics | Allele Discrimination (Need Sequence-Verified standards) |